Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers
- 11 March 2004
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 19 (6) , 655-662
- https://doi.org/10.1111/j.1365-2036.2004.01893.x
Abstract
Proton pump inhibitors control gastric acidity better during the day than at night, when nocturnal acid breakthrough can occur. Tenatoprazole is a novel proton pump inhibitor with a seven-fold longer plasma half-life. Aim : To compare the effects of tenatoprazole 20 mg (T20), tenatoprazole 40 mg (T40) and esomeprazole 40 mg (E40) on intragastric acidity in healthy volunteers. This randomized, three-period, cross-over study enrolled 18 Helicobacter pylori-negative volunteers, who received E40, T20 and T40 once daily for 7 days with a 14-day washout between periods. Twenty-four-hour gastric pH monitoring was performed on day 7. Serum gastrin was assessed on day 8. T40 induced a more potent acid inhibition than T20 (24-h median pH: 4.6 vs. 4.0, P < 0.01; daytime: 4.5 vs. 3.9, P < 0.01; night-time: 4.7 vs. 4.1, P < 0.05). T40 was more potent than E40 (24-h median pH: 4.6 vs. 4.2, P < 0.05; night-time: 4.7 vs. 3.6, P < 0.01); the pH > 4 holding time was higher during the night for T40 than for E40: 64.3% vs. 46.8%, P < 0.01; the nocturnal acid breakthrough duration was significantly shorter for T40 than for E40. No significant gastrin increase was observed and all drugs were well tolerated. T40 is significantly more potent than T20 and E40 during the night. The therapeutic relevance of this pharmacological advantage deserves further study.Keywords
This publication has 25 references indexed in Scilit:
- PantoprazoleDrugs, 2003
- EsomeprazoleDrugs, 2002
- EsomeprazoleDrugs, 2000
- Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 1998
- A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjectsAlimentary Pharmacology & Therapeutics, 1998
- The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pHJournal of Clinical Gastroenterology, 1997
- Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.Gut, 1996
- Comparison of lansoprazole with omeprazole on 24‐hour pH, acid secretion and serum gastrin in healthy volunteersAlimentary Pharmacology & Therapeutics, 1994
- Clinical Significance of Hypergastrinaemia: Relevance to Gastrin Monitoring During Omeprazole TherapyDigestion, 1992
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992